Summary
Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life.
Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential.
The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system. The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability.
To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential.
The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system. The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability.
To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190133087 |
| Start date: | 01-11-2023 |
| End date: | 31-10-2025 |
| Total budget - Public funding: | 2 115 824,25 Euro - 1 481 076,00 Euro |
Cordis data
Original description
Migraine with aura (MA) affects 4% of the global population, causing severe attacks that strongly impact patients’ quality of life.Currently available treatments are often ineffective, contraindicated or prone to side effects, causing 74% of migraine patients to be unsatisfied with their current treatment. This indicates a large unmet clinical need and a significant commercial potential.
The Rehaler medical device is a unique, patented, non-drug MA treatment that effectively relieves or aborts a high percentage of migraine attacks by modulating CO2 and O2 levels in the central nervous system. The device has a unique commercial advantage by combining 1) A high treatment effect, 2) A low risk profile, and 3) Simplicity, compactness and affordability.
To pave the way for regulatory approval, market launch and wide-scale adoption, we will carry out a large-scale clinical trial to collect gold-standard safety and performance data, while expanding our company team and production capacity.
Status
SIGNEDCall topic
HORIZON-EIC-2023-ACCELERATOROPEN-01Update Date
12-03-2024
Images
No images available.
Geographical location(s)
Structured mapping
